Using Rotenone and Antimycin A

Both inhibit the chain and both generate superoxide.

The Two Inhibitors

AgentTargetSiteSuperoxide mechanism
RotenoneComplex IQ-siteReverse electron transfer at high proton motive force; also from the flavin site
Piericidin AComplex IQ-siteSame class; more potent
Antimycin AComplex IIIQi siteQo-site bypass; substantial superoxide production
MyxothiazolComplex IIIQo siteLess superoxide than antimycin
TTFAComplex II—Weak; requires high concentrations
3-NitropropionateComplex II (SDH)IrreversibleRequires new enzyme synthesis for recovery
Potassium cyanideComplex IV—Highly toxic; fast
OligomycinATP synthase—Not an ETC inhibitor; hyperpolarises

Important distinction. Rotenone and antimycin A are the two inhibitors most often used as "specific ETC blocks", and both are among the most potent mitochondrial superoxide generators available. A phenotype that appears with either could be an inhibition phenotype, an oxidative phenotype, or both.

Part 1 — Concentrations and Time

AgentTypical in vitro rangeNotes
Rotenone0.1–10 µMCells concentrate it in mitochondria; effect is fast
Antimycin A0.1–10 µMAlso fast; superoxide peaks early
Oligomycin1–2 µMTitrate; incomplete blockade inflates ATP-linked estimates
FCCP0.5–2 µMTitrate; over-uncoupling damages membranes

Caveat on concentration. Rotenone's cellular potency depends on mitochondrial content and on membrane potential, because uptake is driven by the potential. Cells with more mitochondria reach a higher intramitochondrial concentration at the same medium concentration, which confounds comparisons between lines.

A second caveat concerns partial inhibition: at low concentrations rotenone inhibits reverse electron transfer and superoxide production without substantially reducing forward electron flow. A "low-dose rotenone" experiment may therefore be measuring redox signalling rather than respiration.

Part 2 — Controls That Separate Inhibition from Oxidation

ControlPurpose
Mitochondria-targeted antioxidant (MitoQ, MitoTEMPO)Tests whether superoxide mediates the phenotype
Extracellular antioxidant (NAC, Trolox)Distinguishes mitochondrial from cytosolic oxidation
Substrate-specific respiration in permeabilised cellsConfirms which complex was inhibited
Complex II-linked respirationShould be unaffected by complex I inhibition
Viability and ATP measurementSeparates bioenergetic from cytotoxic effects
Vehicle (DMSO or ethanol) matchedBoth agents are poorly water-soluble

The first control is the discriminating one. If a mitochondria-targeted antioxidant rescues, the mechanism involves superoxide; if it does not, the mechanism is more likely electron transport itself.

Part 3 — Reversibility and Duration

AgentReversibilityDesign consequence
RotenoneSlowly reversible; washout incompleteShort treatments; avoid washout designs
Antimycin ASlowly reversibleSame
OligomycinReversibleWashout is feasible
FCCPRapidly reversibleWashout is feasible
3-NitropropionateIrreversible (covalent)Recovery requires new enzyme

Caveat on long treatments. Hours of complex inhibition selects for cells with altered mitochondrial content and increased glycolytic capacity. A 48-hour rotenone experiment is partly an adaptation experiment, and the adaptation can dominate the phenotype.

Part 4 — What the Result Supports

ObservationSupportsDoes not support
OCR falls with rotenone, not with antimycin, in a substrate-specific assayComplex I dependence of that substrateGeneral ETC dependence
Phenotype rescued by MitoTEMPOSuperoxide-mediated mechanismWhich complex produced it
Growth arrest with normal ATPBiosynthetic limitationEnergy limitation
Growth arrest with low ATPEnergy limitationWhich biosynthetic route
Resistance after long exposureAdaptationA mechanism

Part 5 — Common Failures

  • • A single concentration used as "complex I inhibition".
  • • Superoxide production not considered, so an oxidative mechanism is reported as bioenergetic.
  • • No mitochondria-targeted antioxidant control.
  • • Washout designs used with poorly reversible inhibitors.
  • • Long treatments interpreted as acute inhibition.
  • • DMSO or ethanol vehicle not matched, at volumes that affect respiration.
  • • Oligomycin assumed to give complete ATP synthase blockade.
  • • Complex II used as a control without checking that it is unaffected.

Part 6 — Where This Article Connects

This is the inhibitor article of the mitochondrial cluster, and it supplies the acute tools that the respiratory chain article describes genetically. It connects to the OXPHOS-dependency article in the amino acid cluster, where complex inhibition is used to test aspartate supply, and to the Seahorse protocol article, where the same agents are injected.

If you need ETC inhibition tested with antioxidant and substrate-specific controls, we can scope the design with you.

Contact EDITGENE to request a project consultation or quote.

Scientific scope and validation note

Potency, superoxide production and reversibility vary with cell type, mitochondrial content, substrate and concentration. The ranges here are starting points.

Inhibition of a complex does not establish that electron transport was the relevant function, because superoxide production and biosynthetic supply change simultaneously.

Scientific interpretation and experimental design

  • • Both inhibitors make superoxide. Control for it.
  • • Uptake depends on potential. Concentration is not exposure.
  • • Low-dose rotenone is a redox experiment.
  • • Washout is limited. Do not design around it.
  • • Long exposure selects. It is an adaptation experiment.
  • • Titrate oligomycin and uncoupler.

Selected references for further reading

  • • Chance B, Williams GR. The respiratory chain and oxidative phosphorylation. Advances in Enzymology. 1956;17:65–134.
  • • Murphy MP. How mitochondria produce reactive oxygen species. Biochemical Journal. 2009;417:1–13.
  • • Brand MD, Nicholls DG. Assessing mitochondrial dysfunction in cells. Biochemical Journal. 2011;435:297–312.

Related Products

Product name Cat.No. Species Gene ID
PBRM1 Knockout A-549 Cell Line EDJ0001-K01 Human 55193 Details Get a Quote
YTHDC1 Knockout A-549 Cell Line EDC07652 Human 91746 Details Get a Quote
TP53 Knockout HCT 116 Cell Line EDC07854 Human 7157 Details Get a Quote
Sirt2 Knockout MH-S Cell Line EDJ-KQ78173 Mouse 64383 Details Get a Quote
TFE3 Knockout KGN Cell Line EDJ-KQ48 Human 7030 Details Get a Quote
Stub1 Knockout MB49 Cell Line EDJ-KQ53 Mouse 56424 Details Get a Quote
ARID1A Knockout SNK-6 Cell Line EDJ-KQ64 Human 8289 Details Get a Quote
Tet1 Knockout Kupffer Cell Line EDJ-KQ88 Mouse 52463 Details Get a Quote
NR1H3 Knockout HEK293T Cell Line EDJ-KQ109 Human 10062 Details Get a Quote
NR1H2 Knockout HEK293T Cell Line EDJ-KQ110 Human 7376 Details Get a Quote
RPS6KB2 Knockout HEK293 Cell Line EDJ-KQ125 Human 6199 Details Get a Quote
SMAD6 Knockout HEK293 Cell Line EDJ-KQ126 Human 4091 Details Get a Quote
JUN Knockout HEK293 Cell Line EDJ-KQ176 Human 3725 Details Get a Quote
JUN Knockout HEK293T Cell Line EDJ-KQ184 Human 3725 Details Get a Quote
ALKBH5 Knockout HEK293 Cell Line EDJ-KQ186 Human 54890 Details Get a Quote
Contact Us
*
*
*
How did you hear about us: